IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms (2016)
- Authors:
- Autor USP: TRAINA, FABÍOLA - FMRP
- Unidade: FMRP
- DOI: 10.18632/oncotarget.6851
- Subjects: REAÇÃO EM CADEIA POR POLIMERASE; APOPTOSE; MUTAÇÃO GENÉTICA; LEUCEMIA
- Keywords: STAT5; Myeloproliferative neoplasms; Apoptosis
- Language: Inglês
- Imprenta:
- Source:
- Título: Oncotarget
- ISSN: 1949-2553
- Volume/Número/Paginação/Ano: v. 7, n. 6, p. 6948-6959, 2016
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
CAMPOS, Paula de Melo et al. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget, v. 7, n. 6, p. 6948-6959, 2016Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.6851. Acesso em: 14 fev. 2026. -
APA
Campos, P. de M., Machado Neto, J. A., Eide, C. A., Savage, S. L., Scopim-Ribeiro, R., Duarte, A. da S. S., et al. (2016). IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget, 7( 6), 6948-6959. doi:10.18632/oncotarget.6851 -
NLM
Campos P de M, Machado Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, Duarte A da SS, Favaro P, Lorand-Metze I, Costa FF, Tognon CE, Druker BJ, Saad STO, Traina F. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms [Internet]. Oncotarget. 2016 ; 7( 6): 6948-6959.[citado 2026 fev. 14 ] Available from: https://doi.org/10.18632/oncotarget.6851 -
Vancouver
Campos P de M, Machado Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, Duarte A da SS, Favaro P, Lorand-Metze I, Costa FF, Tognon CE, Druker BJ, Saad STO, Traina F. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms [Internet]. Oncotarget. 2016 ; 7( 6): 6948-6959.[citado 2026 fev. 14 ] Available from: https://doi.org/10.18632/oncotarget.6851 - Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412
- FMNL1 promotes proliferation and migration of leukemia cells
- SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype
- IRS1 (insulin receptor substrate 1)
- Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell–cell adhesion
- Padronização da investigação laboratorial de anticorpos dirigidos contra fármacos em doadores de sangue e pacientes com anemia hemolítica imune
- Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia
- IL32 expression in peripheral blood CD3+ cells from myelodysplastic syndromes patients
- Hedgehog pathway is deregulated in myelodysplastic syndrome progenitor bone marrow cells
- Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome
Informações sobre o DOI: 10.18632/oncotarget.6851 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
